Clinical trial NCT02970175: Interest of in Situ Terlipressin Administration Before the Realisation of Bronchial Biopsy
Official title: Interest of in Situ Terlipressin Administration Before the Realisation of Bronchial Biopsy
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Bronchial Endoscopy
Keywords: Terlipressin
Lead sponsor: University Hospital, Rouen
Sponsor class: OTHER
First posted: 2016-11-21
Enrollment: 130
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The diagnostic yield of flexible bronchoscopy for the diagnosis of lung cancer depends on the location and the histological type of the lesion, as well as on the number of biopsy samples performed. The increasing number of sampling is also important to provide material for molecular assessment of lung cancer. The French National Institute for Cancer recommends a number of 5 biopsies in order to reach a diagnostic yield of 88%. However, as increasing the number of bronchial biopsies comes with a higher risk of bleeding, the management of endobronchial bleeding may be determinant for the diagnostic yield.

The most recent recommendations of the British Thoracic Society for the management of bronchial bleeding, after bronchial or transbronchial biopsy, are to inject 5 to 10 mL of 1/10000 diluted adrenalin, or cold saline serum (04°C.). The French guidelines also include the use of endobronchial terlipressin, which has local vasoconstriction effect. After endobronchial administration of terlipressin, plasmatic concentrations are low, and are not clinically relevant.

The hypothesis of this clinical trial is that endobronchial instillation of terlipressin before sampling endobronchial tumor will limit the endobronchial bleeding and allow to increase the number of biopsies performed and, eventually, the diagnostic yield.


Eligibility criteria: Inclusion Criteria:

* Patients ≥18 years old
* Patients scheduled to undergo bronchoscopy, presenting a suspicious radiographic lesion and a lesion proximal tumor pace viewable in white light endoscopy and without pathologic diagnosis
* Patient having read and understood the information letter and signed the consent form
* Effective contraception in women of childbearing age

Exclusion Criteria:

* Patients with contraindication to the use of terlipressin:
* septic shock ,
* Hypersensitivity to terlipressin or the excipients or by whom use the product is not recommended:
* Recent history (\<3 months) of acute coronary syndrome (including myocardial infarction) or unbalanced coronary insufficiency, or disorders of the ventricular heart rate.
* severe uncontrolled hypertension,
* cerebrovascular insufficiency and ischemic stroke of recent origin (\<3 months).
* severe arterial occlusive lower extremities,
* severe chronic renal impairment (GFR \<20 ml / min).
* Patients receiving uninterrupted antiplatelet therapy during 5 days before endoscopy (7 days for Clopidogrel Related), including low dose aspirin (≤ 75 mg / day).
* Patients receiving anticoagulant therapy:
* Unfractionated heparin within 12 hours before endoscopy.
* low molecular weight heparin within 24 hours before endoscopy.
* Patients with bleeding disorders defined by TP below 70% or TCA ratio patient / control greater than 1.3.
* Patients with thrombocytopenia less than 100 g / L.
* Subjects misunderstanding of spoken and written French
* Person under guardianship or deprived of liberty by judicial or administrative decision (under Article L1121-6 and L1121-8 of Public Health Code
* Pregnant or lactating women, premenopausal women without adequate contraception
* Patient participating in other drug testing or participating in another drug test in the previous month

Primary outcomes:
measure: Number of biopsy realized during the endoscopy
timeFrame: Day 1
Secondary outcomes:
measure: Number of biopsy allowing an histological diagnosis
timeFrame: Day 1
measure: Number of adverse events due to terlipressin administration
timeFrame: Day 1
Other outcomes:
Locations:
city: Rouen
country: France
facility: Rouen University Hospital
Study officials:
affiliation: University Hospital, Rouen
name: Mathieu SALAUN, MD
role: PRINCIPAL_INVESTIGATOR
References: